Regeneron Pharmaceuticals, Inc. and Walgreens Boots Alliance, Inc.: SG&A Spending Patterns Compared

SG&A Spending: Regeneron vs. Walgreens Boots Alliance

__timestampRegeneron Pharmaceuticals, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 201450475500017992000000
Thursday, January 1, 201583852600022400000000
Friday, January 1, 2016117769700023910000000
Sunday, January 1, 2017132043300023813000000
Monday, January 1, 2018155620000024694000000
Tuesday, January 1, 2019183480000023557000000
Wednesday, January 1, 2020134600000025436000000
Friday, January 1, 2021182490000024586000000
Saturday, January 1, 2022211590000027295000000
Sunday, January 1, 2023263130000034205000000
Monday, January 1, 2024295440000028113000000
Loading chart...

Cracking the code

SG&A Spending Patterns: A Tale of Two Giants

In the ever-evolving landscape of the pharmaceutical and retail sectors, understanding spending patterns is crucial. Regeneron Pharmaceuticals, Inc. and Walgreens Boots Alliance, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Regeneron's SG&A expenses surged by over 400%, peaking at approximately $2.6 billion in 2023. This reflects their aggressive expansion and investment in innovation. Meanwhile, Walgreens Boots Alliance maintained a steady increase, with a 44% rise over the same period, reaching around $25.5 billion in 2023. This stability underscores their focus on operational efficiency and market penetration. Notably, 2024 data for Regeneron is missing, hinting at potential strategic shifts. These insights reveal how each company navigates its unique challenges and opportunities, offering a window into their strategic priorities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025